Abstract：
OBJECTIVE: To present the initial prospective clinical assessment of the ILY® robotic ureteroscopy manipulator platform, focusing on its safety and effectiveness.
METHODS: Data gathered from 31 kidney units which underwent elective robotic flexible ureteroscopy (FURS) for renal stone management utilizing the ILY® robotic system. Patient demographics, stone characteristics, surgical durations, perioperative and post-operative complications, and follow-up parameters were collected. Our primary outcome was evaluating the efficacy and safety of the ILY® robotic ureteroscopy for treating kidney stones. Therefore, we analyzed complication rates, surgical durations, and the stone-free rate during follow-up.
RESULTS: Our cohort consisted of 29 patients, presenting with 45 stones with a median volume of 736.22 mm3. The median operation time was 85 min, accompanied by 3 min for robot draping, 3.5 min for robot docking, 48 min of console operation, and lasing time of 36.75 min. Post operative stay for all patients was 1 day, while complications were observed in 9.68% of cases. Notably, all complications were classified as CVD (Clavien-Dindo) class 1 due to pain requiring emergency department visit. The stone-free rate achieved was 93.55%, and none of the patient required reoperation for the treated stone.
CONCLUSIONS: In the first prospective clinical experience of the ILY® robotic FURS, we demonstrated its efficacy and safety. To further investigate its clinical practical value, additional investigations are warranted, including direct comparative analyses with manual flexible ureteroscopy techniques.
METHODS: Data gathered from 31 kidney units which underwent elective robotic flexible ureteroscopy (FURS) for renal stone management utilizing the ILY® robotic system. Patient demographics, stone characteristics, surgical durations, perioperative and post-operative complications, and follow-up parameters were collected. Our primary outcome was evaluating the efficacy and safety of the ILY® robotic ureteroscopy for treating kidney stones. Therefore, we analyzed complication rates, surgical durations, and the stone-free rate during follow-up.
RESULTS: Our cohort consisted of 29 patients, presenting with 45 stones with a median volume of 736.22 mm3. The median operation time was 85 min, accompanied by 3 min for robot draping, 3.5 min for robot docking, 48 min of console operation, and lasing time of 36.75 min. Post operative stay for all patients was 1 day, while complications were observed in 9.68% of cases. Notably, all complications were classified as CVD (Clavien-Dindo) class 1 due to pain requiring emergency department visit. The stone-free rate achieved was 93.55%, and none of the patient required reoperation for the treated stone.
CONCLUSIONS: In the first prospective clinical experience of the ILY® robotic FURS, we demonstrated its efficacy and safety. To further investigate its clinical practical value, additional investigations are warranted, including direct comparative analyses with manual flexible ureteroscopy techniques.
摘要：
目的：为呈现ILY®输尿管镜机器人操纵器平台的初步前瞻性临床评估，注重其安全性和有效性。
方法：从31个肾脏单位收集的数据，这些单位接受了选择性机器人输尿管软镜（FURS），用于利用ILY®机器人系统进行肾结石管理。患者人口统计学，石材特性,手术持续时间,围手术期和术后并发症，并收集随访参数。我们的主要结果是评估ILY®机器人输尿管镜检查治疗肾结石的有效性和安全性。因此,我们分析了并发症发生率,手术持续时间,和随访期间的无石率。
结果：我们的队列包括29名患者，呈现45块石头，中位体积为736.22mm3。中位手术时间为85min,伴随着3分钟的机器人悬垂，机器人对接3.5分钟，控制台操作48分钟,激光时间为36.75min。所有患者术后住院时间均为1天，9.68%的病例出现并发症。值得注意的是,由于疼痛需要急诊就诊,所有并发症均被归类为CVD(Clavien-Dindo)1级.达到的无石率为93.55％，没有一个病人需要再次手术治疗的结石。
结论：在ILY®机器人FURS的第一个前瞻性临床经验中，我们证明了其有效性和安全性.进一步探讨其临床实用价值,需要进一步调查，包括与人工输尿管软镜技术的直接比较分析。
方法：从31个肾脏单位收集的数据，这些单位接受了选择性机器人输尿管软镜（FURS），用于利用ILY®机器人系统进行肾结石管理。患者人口统计学，石材特性,手术持续时间,围手术期和术后并发症，并收集随访参数。我们的主要结果是评估ILY®机器人输尿管镜检查治疗肾结石的有效性和安全性。因此,我们分析了并发症发生率,手术持续时间,和随访期间的无石率。
结果：我们的队列包括29名患者，呈现45块石头，中位体积为736.22mm3。中位手术时间为85min,伴随着3分钟的机器人悬垂，机器人对接3.5分钟，控制台操作48分钟,激光时间为36.75min。所有患者术后住院时间均为1天，9.68%的病例出现并发症。值得注意的是,由于疼痛需要急诊就诊,所有并发症均被归类为CVD(Clavien-Dindo)1级.达到的无石率为93.55％，没有一个病人需要再次手术治疗的结石。
结论：在ILY®机器人FURS的第一个前瞻性临床经验中，我们证明了其有效性和安全性.进一步探讨其临床实用价值,需要进一步调查，包括与人工输尿管软镜技术的直接比较分析。
